4 news items
FibroGen Announces Presentation of Positive Interim Data from the Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) at the 2024 American Society of Clinical Oncology Annual Meeting
FGEN
23 May 24
FibroGen's strategy, future plans and prospects, including statements regarding FG-3246, its clinical programs and those of its collaboration partner Fortis
FibroGen Reports First Quarter 2024 Financial Results
FGEN
6 May 24
. Forward-Looking Statements This release contains forward-looking statements regarding FibroGen's strategy, future
Why Ulta Beauty Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
ABAT
ABIO
ACORQ
3 Apr 24
strategy including a stock buyback program of up to $5 million.
Next.e.GO N.V
FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer
FGEN
2 Apr 24
-Looking Statements This release contains forward-looking statements regarding FibroGen's strategy, future plans and prospects
- Prev
- 1
- Next